NASDAQ: AMGN - Amgen

Yield per half year: +14.11%
Sector: Healthcare

Share chart Amgen


About

Amgen Inc. открывает, разрабатывает, производит и поставляет терапевтические препараты для людей по всему миру. Основное внимание уделяется воспалениям, онкологии / гематологии, здоровью костей, сердечно-сосудистым заболеваниям, нефрологии и неврологии.

More details
Продукция компании включает Enbrel для лечения псориаза, ревматоидного артрита и псориатического артрита; Neulasta, которая снижает вероятность заражения из-за низкого количества лейкоцитов у онкологических больных; Prolia для лечения остеопороза у женщин в постменопаузе; Xgeva для предотвращения событий, связанных со скелетом; Otezla для лечения взрослых пациентов с бляшечным псориазом, псориатическим артритом и язвами в полости рта, связанными с болезнью Бехесета; Аранесп для лечения более низкого, чем обычно, количества эритроцитов и анемии; KYPROLIS для лечения пациентов с рецидивирующей или рефрактерной множественной миеломой; и Repatha, снижающий риск инфаркта миокарда, инсульта и коронарной реваскуляризации. Он также продает Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar / Mimpara, NEUPOGEN, IMLYGIC, Corlanor и AVSOLA. Amgen Inc. обслуживает поставщиков медицинских услуг, включая врачей или их клиники, диализные центры, больницы и аптеки. Она распространяет свою продукцию через оптовых фармацевтических дистрибьюторов, а также по прямым каналам продаж. Компания имеет соглашения о сотрудничестве с Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd .; «Эли Лилли и компания»; и Datos Health. Amgen Inc. была основана в 1980 году, ее штаб-квартира находится в Таузенд-Оукс, Калифорния.


Main settings

Цена ао 310.15
P/E 18.52
P/S 6.22
P/BV 15.01
EV/EBITDA 16.22
Дивиденд ао 8.52
Див.доход ао 3.23
EBITDA 10.43
Сайт http://www.amgen.com
Число акций ао 0.538 млрд
Выручка 23.36
ISIN US0311621009
Change price per day: -0.2153% (306.5)
Change price per week: -2.12% (312.47)
Change price per month: +12.03% (273.01)
Change price per 3 month: +5.76% (289.18)
Change price per half year: +14.11% (268.02)
Change price per year: +39.95% (218.53)
Change price per 3 year: +42.5% (214.62)
Change price per 5 year: +19.81% (255.27)
Change price per year to date: +7.63% (284.16)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 6.22 2
P/BV 15.01 1
P/E 18.52 6
EV/EBITDA 16.22 4
Total:

Efficiency

Title Value Grade
ROA, % 8.28 3
ROE, % 135.79 10
Total:

Dividends

Title Value Grade
Div yield, % 3.13 6
DSI 0.93 9
Total:

Debt

Title Value Grade
Debt/EBITDA 8.18 1
Total:

Growth impulse

Title Value Grade
Profit growth, % 25.46 5
Share price growth, % 43.74 9
Dividend growth, % 30.57 6
Total:

Dividends

Dividends, % Dividends Result of period Buy before Register closing date Payment before
0.73% 2.25 I кв. 2024 14.05.2024 16.05.2024 31.05.2024
0.76% 2.25 IV кв. 2023 13.02.2024 15.02.2024 01.03.2024
0.85% 2.13 I кв. 2023 15.05.2023 17.05.2023 01.06.2023
0.88% 2.13 IV кв. 2022 10.02.2023 14.02.2023 01.03.2023
0.71% 1.94 III кв. 2022 14.11.2022 16.11.2022 01.12.2022
0.8% 1.94 I кв. 2022 13.05.2022 16.05.2022 31.05.2022
0.87% 1.76 III кв. 2021 12.11.2021 15.11.2021 30.11.2021

Insider trading

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
19.09.2023 19.09.2023 AMGEN INC
10% Owner
Buy 17 30 000 000 1764705 0 0.31 link
09.11.2022 10.11.2022 Khosla Rachna
SVP, Business Development
Sale 292.9 113 352 387 0 0 link
10.05.2022 10.05.2022 Graham Jonathan P
EVP, Gen. Counsel & Secy.
Sale 241.81 3 264 440 13500 0 0 link
04.02.2021 05.02.2021 Graham Jonathan P
EVP, Gen. Counsel & Secy.
Sale 236.51 2 627 630 11110 0 0 link
13.01.2021 14.01.2021 SUGAR RONALD D
Director
Sale 235.99 235 990 1000 0 0 link
13.01.2021 14.01.2021 SUGAR RONALD D
Director
Buy 71.64 71 640 1000 0 0 link

Main owners

Institutions Volume Share, %
Vanguard Group Inc 49042553 9.15
Blackrock Inc. 47812390 8.92
State Street Corporation 29463970 5.5
PRIMECAP Management Company 14591468 2.72
Morgan Stanley 14434062 2.69
Geode Capital Management, LLC 12339956 2.3
Charles Schwab Investment Management, Inc. 10393110 1.94
Wells Fargo & Company 7488777 1.4
Capital Research Global Investors 6706651 1.25
Price (T.Rowe) Associates Inc 6564710 1.22

Contained in ETF

ETF Share, % Profitability for 1 year, % Dividends, %
Global X Longevity Thematic ETF 2.72 38.50 0.36
Pacific Global US Equity Income ETF 1.43 4.60
Direxion MSCI USA ESG - Leaders vs. Laggards ETF 2.39 29.10 22.81
Arrow QVM Equity Factor ETF 0.29 3.38
Pacer Salt Low truBeta US Market ETF 1.15 20.77 2.09
Franklin LibertyQ Global Dividend ETF 2.12 30.37 2.67
iShares Evolved U.S. Innovative Healthcare ETF 4.27 27.98 2.79
Franklin LibertyQ Global Equity ETF 1.04 25.84 2.05
John Hancock Multifactor Healthcare ETF 1.84 29.34 1.62
UVA Dividend Value ETF 2.27 3.23
US Equity Dividend Select ETF 1.4 39.67 2.97
IQ Engender Equality ETF 1.44 1.49
FinEx USA UCITS ETF 0.36 54.54
БПИФ АЛЬФА_КАП ТЕХНОЛОГИИ 100 0
FinEx RUB GLOBAL EQUITY UC ETF 0.09 48.06
FinEx USD GLOBAL EQUITY UC ETF 0.09 37.73
Invesco Nasdaq Biotechnology ETF 9.26 0.84
iShares Global Healthcare ETF 2.23 23.74 1.31
Schwab US Dividend Equity ETF 4.39 39.17 3.36
Health Care Select Sector SPDR Fund 3.11 28.02 1.51
SPDR Dow Jones Industrial Average ETF Trust 5.19 25.45 1.70
Vanguard Health Care ETF 2.49 29.53 1.30
iShares MSCI USA Momentum Factor ETF 1.71 17.83 0.78
First Trust Value Line Dividend Index Fund 0.63 31.24 2.19
iShares Biotechnology ETF 9.31 31.10 0.30
SPDR S&P Biotech ETF 1.22 23.57 0.02
iShares U.S. Healthcare ETF 3.01 29.01 3.37
Amplify CWP Enhanced Dividend Income ETF 4.19 24.14 4.47
Fidelity MSCI Health Care Index ETF 2.74 29.23 1.32
First Trust Nasdaq-100 Equal Weighted Index Fund 1.15 30.52 0.69
Distillate US Fundamental Stability & Value ETF 1.8 28.37 1.26
Nuveen ESG Large-Cap Value ETF 1.83 32.37 2.38
Direxion NASDAQ-100 Equal Weighted Index Shares 1.15 30.67 0.86
Direxion Daily S&P Biotech Bull 3x Shares 0.84 32.14 0.36
First Trust NYSE Arca Biotechnology Index Fund 3.75 11.39
iShares ESG Advanced MSCI USA ETF 0.91 31.83 1.08
Invesco S&P 500 Equal Weight Health Care ETF 1.84 0.63
Invesco S&P 100 Equal Weight ETF 1.12 36.88 1.86
ProShares UltraPro Dow30 3.05 82.30 0.76
VanEck Biotech ETF 16.16 38.53 0.42
ProShares Ultra Dow30 3.63 51.77 0.53
Invesco Dow Jones Industrial Average Dividend ETF 5.36 29.20 3.40
iShares MSCI Global Sustainable Development Goals ETF 2.69 24.18 1.79
Invesco Pharmaceuticals ETF 6.34 28.63 0.91
Invesco Biotechnology & Genome ETF 5.46 37.15 0.06
First Trust Dow 30 Equal Weight ETF 3.75 28.44 1.84
FlexShares US Quality Large Cap Index Fund 1.36 31.70 1.08
Direxion Daily Healthcare Bull 3x Shares 2.74 93.37 1.62
Core Alternative ETF 2.71 11.09 1.28
First Trust Nasdaq-100 Ex-Technology Sector Index Fund 1.93 28.29 1.16
AXS Change Finance ESG ETF 1.13 33.25 0.87
WisdomTree Global High Dividend Fund 1.11 28.71 4.17
Federated Hermes U.S. Strategic Dividend ETF 3.08 3.32
ProShares Ultra Nasdaq Biotechnology 6.35 57.51 0.13
ProShares Ultra Health Care 2.3 61.62 0.33
Global X Dow 30 Covered Call ETF 5.19 6.73
Tema Obesity & Cardiometabolic ETF 5.58
Global X Aging Population ETF 3.37 20.87 0.91
VanEck Durable High Dividend ETF 3.07 22.12 3.37
Goldman Sachs Future Health Care Equity ETF 4.68 0.52
Point Bridge America First ETF 0.82 43.63 1.47
First Trust Nasdaq Pharmaceuticals ETF 4.14 10.11 1.41
Tema Oncology ETF 3.41 0.54
iShares ESG MSCI USA Min Vol Factor ETF 1.45 1.65

Similar companies



Company management

Head Job title Payment Year of birth
Mr. Robert A. Bradway Chairman, CEO & President 5.49M 1963 (61 year)
Mr. Peter H. Griffith Executive VP & CFO 2.57M 1959 (65 years)
Mr. Esteban Santos Executive Vice President of Operations 2.52M 1968 (56 years)
Dr. David M. Reese M.D. Executive VP & Chief Technology Officer 2.83M 1963 (61 year)
Mr. Murdo Gordon Executive Vice President of Global Commercial Operations 2.72M 1967 (57 years)
Mr. Mike Zahigian Senior VP & Chief Information Officer N/A
Mr. Jonathan P. Graham Executive VP, General Counsel & Secretary 2.44M 1961 (63 years)
Mr. Matthew C. Busch Chief Accounting Officer & VP of Finance N/A 1974 (50 years)
Dr. James E. Bradner M.D. Executive VP of Research and Development & Chief Scientific Officer N/A 1972 (52 years)
Justin G. Claeys Vice President of Investor Relations N/A

About company

Address: United States, Thousand Oaks, CA -, One Amgen Center Drive - open in Google maps, open in Yandex maps
Website: http://www.amgen.com
Phone: +805 447 1000